Nephroprotective effects with SGLT2i in CKD patients - PACE-CME

Nephroprotective effects with SGLTi in CKD patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
ESC 2020
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
- Prof. Freek Verheugt, MD
No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19
No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19
ESC 2020
No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19
- Prof. Renato D. Lopes, MD, PhD
Advantages of the digital 2020 ESC Congress
Advantages of the digital 2020 ESC Congress
ESC 2020
Advantages of the digital 2020 ESC Congress
- Prof. Barbara Casadei, MD
A step ahead in the management of HFmrEF and HFpEF
A step ahead in the management of HFmrEF and HFpEF
ESC 2020
A step ahead in the management of HFmrEF and HFpEF
- Prof. Burkert Pieske